Researchers Transform Cancer Therapy to Make it 20,000 Times More Effective

Researchers re-engineered the structure of the commonly ussed chemotherapy drug 5-fluorouracil (5FU) into that of a “spherical nucleic acid” — a nanostructure that weaves the drug directly into DNA strands coating tiny spheres, making its cancer cell-killing ability 20,000 more effective, while also reducing its toxicity.

Study Reveals Potential New Way to Treat Autoimmune Disease

A new study by researchers at Swansea University has revealed a new way to potentially treat certain autoimmune diseases by targeting a protein that helps regulate energy production in immune cells.

Combination Immunotherapy Helps Overcome Melanoma Treatment Resistance

Early data from a Phase II clinical trial show a combination of immunotherapy medications can activate a robust immune response and help overcome treatment resistance in patients with refractory melanoma.

Efgartigimod Treatment Increases Spending for CIDP Patients

A new study has found that introducing efgartigimod alfa as a treatment option in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who are currently receiving subcutaneous immune globulin (IG) or intravenous IG would result in substantially increased spending in the treatment of CIPD.

Therapeutic Plasma Exchange: A Promising New Treatment for Sepsis and Septic Shock

Therapeutic plasma exchange may improve outcomes for patients diagnosed with sepsis or septic shock, but funding is needed to conduct needed clinical trials.

FDA Approves Implantable Device to Treat RA Patients

SetPoint System, a neuroimmune modulation device, has been approved by the U.S. Food and Drug Administration to treat adults with moderately to severely active rheumatoid arthritis who have had an inadequate response, loss of response or intolerance to one or more biological or targeted synthetic disease-modifying anti-rheumatic drugs.

Takeda’s New Devices for Hyqvia Infusion Can Reduce Preparation Steps By Up to One-Half

The U.S. Food and Drug Administration has granted 510(k) clearance to Takeda’s HyHub and HyHub Duo for patients 17 years of age and older that allow HYQVIA [immune globulin infusion (human), 10% with recombinant human hyaluronidase] to be transferred from vials without using a needle in a home environment or clinical setting. 

Myths & Facts: GLP-1 Drugs for Weight Loss

Misconceptions about GLP-1 drugs could interfere with patients’ efforts to achieve their weight-loss goals.

Diagnosing and Treating Infant Botulism

Since the approval of BabyBIG, the only treatment for this rare but life-threatening disease affecting infants mostly under 6 months, the mortality rate is now less than 15 percent.

Update on Rabies

Though mostly eradicated in the U.S., treatment for rabies must begin immediately with hyperimmune globulin and vaccines.